Payment overview · 2025
General Payments
$753.71
42 reported records · 16 companies
Healthcare provider profile · identity verified
Rewais Morcus, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · STATEN ISLAND, NY · NPI 1730468380
Verified facts
What the public records show
CMS Open Payments records show Rewais Morcus, M.D. received $753.71 in general payments during 2025 across 42 reported records.
Janssen Biotech, Inc. accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Tagrisso.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tagrisso by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $123.86 | 16.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.41 | 13.8% | 6 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $103.62 | 13.8% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $87.58 | 11.6% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $41.62 | 5.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.72 | 5.3% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $37.40 | 5.0% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $36.77 | 4.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.60 | 4.9% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $29.25 | 3.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.30 | 3.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.39 | 2.8% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $19.00 | 2.5% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $17.06 | 2.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.48 | 2.2% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $15.65 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $753.71 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $103.62 | 6 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $87.58 | 5 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $73.64 | 4 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $73.64 | 4 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $52.15 | 3 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $50.22 | 3 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $41.62 | 2 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| Venclexta Normalized: venclexta |
Biological | Genentech USA, Inc. | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $29.25 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| Odomzo Normalized: odomzo |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 26 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 203 | 33 |
| Eliquis | Apixaban | 195 | 26 |
| Gabapentin | Gabapentin | 130 | 15 |
| Silver Sulfadiazine | Silver Sulfadiazine | 106 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 105 | 16 |
| Donepezil Hcl | Donepezil Hcl | 102 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 86 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 11 |
| Furosemide | Furosemide | 72 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 67 | 11 |
| Losartan Potassium | Losartan Potassium | 65 | suppressed |
| Lorazepam | Lorazepam | 62 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | suppressed |
| Famotidine | Famotidine | 60 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 58 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | suppressed |
| Nifedipine Er | Nifedipine | 57 | 12 |
| Mirtazapine | Mirtazapine | 54 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 51 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | suppressed |
| Diazepam | Diazepam | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Clozapine | Clozapine | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Lisinopril | Lisinopril | 38 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 38 | 19 |
| Levofloxacin | Levofloxacin | 36 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | suppressed |
| Xtandi | Enzalutamide | 29 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Nucynta | Tapentadol Hcl | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | 17 |
| Enoxaparin Sodium | Enoxaparin Sodium | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Hydroxyurea | Hydroxyurea | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Lupron Depot | Leuprolide Acetate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Lenvima | Lenvatinib Mesylate | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Tagrisso | Osimertinib Mesylate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $753.71 · 42 records | Janssen Biotech, Inc. | BESREMI, CABOMETYX, DARZALEX, ENHERTU, FRUZAQLA, IBRANCE, LYNPARZA, MONJUVI, MONOFERRIC, Nubeqa, OPDIVO, Odomzo, PADCEV, PYRUKYND, REBLOZYL, SARCLISA, SCEMBLIX, Stivarga, TAGRISSO, TALVEY, TECVAYLI, TUKYSA, Venclexta, Vitrakvi, ZYNYZ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Tagrisso play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error